Gemcitabine, sold under the brand name Gemzar, among others, is a chemotherapy medication used to treat a number of types of cancer. These cancers include breast cancer, ovarian cancer, non-small cell lung cancer, pancreatic cancer, and bladder cancer. It is given by slow injection into a vein.
|Trade names||Gemzar, others|
|Synonyms||2', 2'-difluoro 2'deoxycytidine, dFdC|
Short infusions: 32–94 minutes|
Long infusions: 245–638 minutes
|Chemical and physical data|
|Molar mass||263.198 g/mol|
|3D model (JSmol)|
Common side effects include bone marrow suppression, liver and kidney problems, nausea, fever, rash, shortness of breath, mouth sores, diarrhea, neuropathy, and hair loss. Use during pregnancy will likely result in harm to the baby. Gemcitabine is in the nucleoside analog family of medication. It works by blocking the creation of new DNA, which results in cell death.
Gemcitabine was patented in 1983 and was approved for medical use in 1995. Generic versions were introduced in Europe in 2009 and in the US in 2010. It is on the World Health Organization's List of Essential Medicines, the most effective and safe medicines needed in a health system. The wholesale cost in the developing world is about US$24.41 to $316.99 per gram vial. In the United Kingdom a 1 g vial costs the NHS approximately £155.
Gemcitabine is used in various carcinomas. It is used as a first-line treatment alone for pancreatic cancer, and in combination with cisplatin for advanced or metastatic bladder cancer and advanced or metastatic non-small cell lung cancer. It is used as a second-line treatment in combination with carboplatin for ovarian cancer and in combination with paclitaxel for breast cancer that is metastatic or cannot be surgically removed.
Contraindications and drug interactionsEdit
Taking gemcitabine can also affect fertility in men and women, sex life, and menstruation. Women taking gemcitabine should not become pregnant, and pregnant and breastfeeding women should not take it.
Gemcitabine is a chemotherapy drug that works by killing any cells that are dividing. Cancer cells divide rapidly and so are targeted at higher rates by gemcitabine, but many essential cells divide rapidly as well, including cells in skin, the scalp, the lining of the stomach, and bone marrow, resulting in adverse effects.:265
The gemcitabine label carries warnings that it can suppress bone marrow function and cause loss of white blood cells, loss of platelets, and loss of red blood cells, that it should be used carefully in people with liver, kidney, or cardiovascular disorders, that people taking it should not take live vaccines, that it may cause posterior reversible encephalopathy syndrome, that it may cause capillary leak syndrome, that it may cause severe lung conditions like pulmonary edema, pneumonia, and adult respiratory distress syndrome, and that it may harm sperm.
Very common (more than 10% of people develop them) adverse effects include difficulty breathing, low white and red blood cells counts and low platelet counts, vomiting and nausea, elevated transaminases, rashes and itchy skin, hair loss, blood and protein in urine, flu-like symptoms, and edema.
Common adverse effects (occurring in 1–10% of people) include fever, loss of appetite, headache, difficulty sleeping, tiredness, cough, runny nose, diarrhea, mouth and lip sores, sweating, back pain, and muscle pain.
Gemcitabine is hydrophilic and must be transported into cells via molecular transporters for nucleosides (the most common transporters for gemcitabine are SLC29A1 SLC28A1, and SLC28A3). After entering the cell, gemcitabine is first modified by attaching a phosphate to it, and so it becomes gemcitabine monophosphate (dFdCMP). This is the rate-determining step that is catalyzed by the enzyme deoxycytidine kinase (DCK). Two more phosphates are added by other enzymes. After the attachment of the three phosphates gemcitabine is finally pharmacologically active as gemcitabine triphosphate (dFdCTP).
When gemcitabine is incorporated into DNA it allows a native, or normal, nucleoside base to be added next to it. This leads to “masked chain termination” as gemcitabine is a “faulty” base, but due to its neighboring native nucleoside it eludes the cell's normal repair system (base-excision repair). Thus, incorporation of gemcitabine into the cell's DNA creates an irreparable error that leads to inhibition of further DNA synthesis, and thereby leading to cell death.
The form of gemcitabine with two phosphates attached (dFdCDP) also has activity; it inhibits the enzyme ribonucleotide reductase (RNR), which is needed to create new nucleotides. The lack of nucleotides drives the cell to uptake more of the components it needs to make nucleotides from outside the cell, which increases uptake of gemcitabine as well.
The synthesis described and pictured below is the original synthesis done in the Eli Lilly Company labs. Synthesis begins with enantiopure D-glyceraldehyde (R)-2 as the starting material which can made from D-mannitol in 2–7 steps. Then fluorine is introduced by a "building block" approach using ethyl bromodifluroacetate. Then, Reformatsky reaction under standard conditions will yield a 3:1 anti/syn diastereomeric mixture, with one major product. Separation of the diastereomers is carried out via HPLC, thus yielding the anti-3 gemcitabine in a 65% yield. At least two other full synthesis methods have also been developed by different groups.
Gemcitabine was first synthesized in Larry Hertel's lab at Eli Lilly during the early 1980s. It was intended as an antiviral drug, but preclinical testing showed that it killed leukemia cells in vitro.
During the early 1990s gemcitabine was studied in clinical trials. The pancreatic cancer trials found that gemcitabine increased one-year survival time significantly, and it was approved in the UK in 1995 and approved by the FDA in 1996 for pancreatic cancers. In 1998, gemcitabine received FDA approval for treating non-small cell lung cancer and in 2004, it was approved from metastatic breast cancer.
European labels were harmonized by the EMA in 2008.
By 2008, Lilly's worldwide sales of gemcitabine were about $1.7 billion; at that time its US patents were set to expire in 2013 and its European patents in 2009. The first generic launched in Europe in 2009, and patent challenges were mounted in the US which led to invalidation of a key Lilly patent on its method to make the drug. Generic companies started selling the drug in the US in 2010 when the patent on the chemical itself expired. Patent litigation in China made headlines there and was resolved in 2010.
Society and cultureEdit
As of 2017, gemcitabine was marketed under many brand names worldwide: Abine, Accogem, Acytabin, Antoril, axigem, Bendacitabin, Biogem, Boligem, Celzar, Citegin, Cytigem, Cytogem, Daplax, DBL, Demozar, Dercin, Emcitab, Enekamub, Eriogem, Fotinex, Gebina, Gemalata, Gembin, Gembine, Gembio, Gemcel, Gemcetin, Gemcibine, Gemcikal, Gemcipen, Gemcired, Gemcirena, Gemcit, Gemcitabin, Gemcitabina, Gemcitabine, Gemcitabinum, Gemcitan, Gemedac, Gemflor, Gemful, Gemita, Gemko, Gemliquid, Gemmis, Gemnil, Gempower, Gemsol, Gemstad, Gemstada, Gemtabine, Gemtavis, Gemtaz, Gemtero, Gemtra, Gemtro, Gemvic, Gemxit, Gemzar, Gentabim, Genuten, Genvir, Geroam, Gestredos, Getanosan, Getmisi, Gezt, Gitrabin, Gramagen, Haxanit, Jemta, Kalbezar, Medigem, Meditabine, Nabigem, Nallian, Oncogem, Oncoril, Pamigeno, Ribozar, Santabin, Sitagem, Symtabin, Yu Jie, Ze Fei, and Zefei.
Research into pharmacogenomics and pharmacogenetics has been ongoing. As of 2014, it was not clear whether or not genetic tests could be useful in guiding dosing and which people respond best to gemcitabine. However, it appears that variation in the expression of proteins (SLC29A1, SLC29A2, SLC28A1, and SLC28A3) used for transport of gemcitabine into the cell lead to variations in its potency. Similarly, the genes that express proteins that lead to its inactivation (deoxycytidine deaminase, cytidine deaminase, and NT5C) and that express its other intracellular targets (RRM1, RRM2, and RRM2B) lead to variations in response to the drug. Research has also been ongoing to understand how mutations in pancreatic cancers themselves determine response to gemcitabine.
- "Gemcitabine International Brands". Drugs.com. Archived from the original on 25 May 2014. Retrieved 6 May 2017.
- "Gemcitabine Hydrochloride". The American Society of Health-System Pharmacists. Archived from the original on 2 February 2017. Retrieved 8 December 2016.
- National Cancer Institute. "FDA Approval for Gemcitabine Hydrochloride". National Cancer Institute. Archived from the original on 5 April 2017. Retrieved 22 April 2017.
- Fischer, Janos; Ganellin, C. Robin (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 511. ISBN 9783527607495. Archived from the original on 2016-12-20.
- Myers, Calisha (13 March 2009). "Gemcitabine from Actavis launched on patent expiry in EU markets". FierceBiotech. Archived from the original on 11 September 2017.
- "Press release: Hospira launches two-gram vial of gemcitabine hydrochloride for injection". Hospira via News-Medical.Net. 16 November 2010. Archived from the original on 2 October 2015.
- "WHO Model List of Essential Medicines (19th List)" (PDF). World Health Organization. April 2015. Archived (PDF) from the original on 13 December 2016. Retrieved 8 December 2016.
- "Gemcitabine". International Drug Price Indicator Guide. Retrieved 8 December 2016.
- British national formulary: BNF 69 (69 ed.). British Medical Association. 2015. p. 590. ISBN 9780857111562.
- "UK label". UK Electronic Medicines Compendium. 5 June 2014. Archived from the original on 10 July 2017. Retrieved 6 May 2017.
- "US Label" (PDF). FDA. June 2014. Archived (PDF) from the original on 16 February 2017. Retrieved 6 May 2017. For label updates see FDA index page for NDA 020509 Archived 2017-04-29 at the Wayback Machine.
- Zhang, XW; Ma, YX; Sun, Y; Cao, YB; Li, Q; Xu, CA (29 March 2017). "Gemcitabine in Combination with a Second Cytotoxic Agent in the First-Line Treatment of Locally Advanced or Metastatic Pancreatic Cancer: A Systematic Review and Meta-Analysis". Targeted Oncology. doi:10.1007/s11523-017-0486-5. PMID 28353074.
- Plentz, RR; Malek, NP (December 2016). "Systemic Therapy of Cholangiocarcinoma". Visceral Medicine. 32 (6): 427–430. doi:10.1159/000453084. PMC 5290432. PMID 28229078.
- Jain, A; Kwong, LN; Javle, M (November 2016). "Genomic Profiling of Biliary Tract Cancers and Implications for Clinical Practice". Current Treatment Options in Oncology. 17 (11): 58. doi:10.1007/s11864-016-0432-2. PMID 27658789.
- Macmillan Cancer Support. "Gemcitabine". Macmillan Cancer Support. Archived from the original on 25 March 2017. Retrieved 6 May 2017.
- Rachel Airley (2009). Cancer Chemotherapy. Wiley-Blackwell. ISBN 0-470-09254-8.
- Siddall, E; Khatri, M; Radhakrishnan, J (16 March 2017). "Capillary leak syndrome: etiologies, pathophysiology, and management". Kidney International. doi:10.1016/j.kint.2016.11.029. PMID 28318633.
- Alvarellos, ML; Lamba, J; Sangkuhl, K; Thorn, CF; Wang, L; Klein, DJ; Altman, RB; Klein, TE (November 2014). "PharmGKB summary: gemcitabine pathway". Pharmacogenetics and genomics. 24 (11): 564–74. doi:10.1097/fpc.0000000000000086. PMC 4189987. PMID 25162786.
- Mini, E; Nobili, S; Caciagli, B; Landini, I; Mazzei, T (May 2006). "Cellular pharmacology of gemcitabine". Annals of Oncology. 17 Suppl 5: v7–12. doi:10.1093/annonc/mdj941. PMID 16807468.
- Cerqueira NM, Fernandes PA, Ramos MJ (2007). "Understanding ribonucleotide reductase inactivation by gemcitabine". Chemistry: A European Journal. 13 (30): 8507–15. doi:10.1002/chem.200700260. PMID 17636467.
- Brown, K; Weymouth-Wilson, A; Linclau, B (10 April 2015). "A linear synthesis of gemcitabine". Carbohydrate research. 406: 71–5. doi:10.1016/j.carres.2015.01.001. PMID 25681996.
- Brown, K; Dixey, M; Weymouth-Wilson, A; Linclau, B (31 March 2014). "The synthesis of gemcitabine". Carbohydrate research. 387: 59–73. doi:10.1016/j.carres.2014.01.024. PMID 24636495.
- Sneader, Walter (2005). Drug discovery: a history. New York: Wiley. p. 259. ISBN 0-471-89979-8.
- "Gemzar". European Medicines Agency. 24 September 2008. Archived from the original on 11 September 2017.
- Myers, Calisha (18 August 2009). "Patent for Lilly's cancer drug Gemzar invalidated". FiercePharma. Archived from the original on 11 September 2017.
- Holman, Christopher M. (Summer 2011). "Unpredictability in Patent Law and Its Effect on Pharmaceutical Innovation" (PDF). Missouri Law Review. 76 (3): 645–693. Archived (PDF) from the original on 2017-09-11.
- Ravicher, Daniel B. (28 July 2010). "On the Generic Gemzar Patent Fight". Seeking Alpha. Archived from the original on 9 December 2012.
- Wang, Mei-Hsin; Alexandre, Daniele (2015). "Analysis of Cases on Pharmaceutical Patent Infringement in Great China". In Rader, Randall R.; et al. Law, Politics and Revenue Extraction on Intellectual Property. Cambridge Scholars Publishing. p. 119. ISBN 9781443879262. Archived from the original on 2017-09-11.
- Dyawanapelly, S; Kumar, A; Chourasia, MK (2017). "Lessons Learned from Gemcitabine: Impact of Therapeutic Carrier Systems and Gemcitabine's Drug Conjugates on Cancer Therapy". Critical reviews in therapeutic drug carrier systems. 34 (1): 63–96. doi:10.1615/CritRevTherDrugCarrierSyst.2017017912. PMID 28322141.
- Birhanu, G; Javar, HA; Seyedjafari, E; Zandi-Karimi, A (April 2017). "Nanotechnology for delivery of gemcitabine to treat pancreatic cancer". Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 88: 635–643. doi:10.1016/j.biopha.2017.01.071. PMID 28142120.
- Dubey, RD; Saneja, A; Gupta, PK; Gupta, PN (10 October 2016). "Recent advances in drug delivery strategies for improved therapeutic efficacy of gemcitabine". European Journal of Pharmaceutical Sciences. 93: 147–62. doi:10.1016/j.ejps.2016.08.021. PMID 27531553.
- Pishvaian, MJ; Brody, JR (15 March 2017). "Therapeutic Implications of Molecular Subtyping for Pancreatic Cancer". Oncology (Williston Park, N.Y.). 31 (3): 159–66, 168. PMID 28299752. Archived from the original on 3 July 2017.
- Krown, SE (September 2011). "Treatment strategies for Kaposi sarcoma in sub-Saharan Africa: challenges and opportunities". Current Opinion in Oncology. 23 (5): 463–8. doi:10.1097/cco.0b013e328349428d. PMC 3465839. PMID 21681092.